J.B. Chemicals & Pharmaceuticals Ltd.

Annual Quarterly₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

View

In ₹ Crore except Per Share 12 Months Ending	Q1 FY24 30/06/2023	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026
Revenue from Operations	896.2	881.7	844.5	861.7	1,004.4	1,000.6	963.5	949.5	1,093.9	1,084.9	1,064.7	904.2
Other Income	5.6	7.7	7.4	16.6	5.9	10.0	8.0	14.5	14.6	15.3	18.3	12.0
Total Income	901.8	889.4	851.9	878.4	1,010.3	1,010.6	971.5	964.0	1,108.5	1,100.2	1,083.0	916.2
Expenses
+ Cost of Materials Consumed	218.8	221.4	198.9	177.2	251.6	179.2	200.2	189.0	241.4	225.3	212.0	233.7
+ Purchases of Stock-in-Trade	80.2	78.2	78.4	175.8	101.0	150.1	109.8	136.0	149.4	121.3	104.3	102.8
+ Changes in Inventories	11.0	-1.4	-3.7	-52.7	-12.9	9.1	6.7	-3.3	-43.7	-1.2	13.1	-62.3
+ Employee Benefit Expense	148.8	148.3	151.7	152.7	166.9	170.6	173.3	176.8	194.3	188.3	191.4	198.7
+ Finance Costs	12.1	10.4	12.5	9.4	5.6	2.1	2.6	1.5	1.1	1.4	1.9	1.2
+ Depreciation & Amortisation	31.4	32.2	34.0	40.7	40.8	41.9	41.9	46.4	42.7	44.4	45.4	50.0
+ Other Expenses	205.4	191.8	196.1	210.6	217.4	221.1	218.9	224.6	251.7	241.6	248.1	230.1
Total Expenses	707.5	680.7	667.9	713.8	770.5	774.0	753.5	770.9	836.9	821.1	816.1	754.3
EBITDA	232.1	243.5	223.1	198.1	280.4	270.5	254.5	226.4	300.9	309.6	295.8	201.1
EBIT	200.7	211.4	189.1	157.4	239.6	228.6	212.6	180.0	258.2	265.2	250.5	151.1
Profit
PBT before Exceptional Items	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	161.9
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-27.2
Pretax Income	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	134.7
+ Current Tax	40.8	44.5	36.2	29.5	54.5	53.9	46.1	46.0	65.6	65.9	63.1	37.7
+ Deferred Tax	11.2	13.6	14.1	9.0	8.5	8.1	9.4	1.4	3.6	5.5	5.9	-4.4
Tax Expense	52.0	58.1	50.4	38.4	63.0	62.0	55.5	47.3	69.2	71.3	69.0	33.3
Net Income	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	101.4
+ Net Income — Continuing Ops	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	101.4
+ Other Comprehensive Income	-8.5	-3.3	1.4	-4.2	7.1	2.7	-14.9	13.6	4.3	5.2	10.0	7.3
Total Comprehensive Income	133.8	147.3	135.0	121.9	184.0	177.3	147.6	159.3	206.7	213.0	207.9	108.7
Net Income to Common	142.3	155.1	133.6	-4.2	—	174.6	162.5	13.6	206.7	207.8	197.9	101.4
Per Share
Basic EPS	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	6.35
Diluted EPS	18.14	9.54	8.46	8.06	11.17	11.00	10.24	9.17	12.75	13.08	12.45	6.32
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	—	13.6	4.3	5.2	10.0	7.3
+ Items NOT to be Reclassified to P&L	-0.2	-3.7	-1.5	0.4	-1.2	-3.3	-1.3	-0.1	-1.3	-5.3	-1.3	4.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	—	-0.0	-0.3	-1.3	-0.3	1.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.9	-0.4	0.1	-0.3	-0.8	-0.3	—	—	—	—	—
+ Items to be Reclassified to P&L	-8.1	-0.7	2.4	-5.1	8.3	5.0	-14.6	14.9	5.2	9.0	10.9	4.1
+ Tax on Items to be Reclassified	—	—	—	—	—	—	—	1.2	-0.1	-0.1	-0.1	0.1
+ Tax on Items to be Reclassified — alt tag	0.3	-0.2	-0.1	-0.5	0.3	-0.2	-0.6	—	—	—	—	—
Comprehensive Income — Owners of Parent	133.8	147.3	135.0	121.9	184.0	177.3	147.6	159.3	4.3	213.0	207.9	7.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	6.35
Diluted EPS — Continuing Operations	18.14	9.54	8.46	8.06	11.17	11.00	10.24	9.17	12.75	13.08	12.45	6.32
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	586.2	583.6	570.9	561.5	664.7	662.2	646.8	627.8	746.8	739.4	735.3	630.0
Gross Margin %	65.41	66.18	67.60	65.15	66.17	66.18	67.13	66.12	68.27	68.15	69.06	69.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	161.9
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-27.2
Net Income Adj (tax-effected)	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	121.8
EPS Adj	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	7.63
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	15.5	15.5	15.5	15.5	15.5	15.5	15.6	15.6	15.6	15.7	15.7	16.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q4 FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.